Ordering Recommendation

Assess risk for lupus nephritis and global systemic lupus erythematosus (SLE) disease activity.

Mnemonic
ANTI-C1Q
Methodology

Semi-Quantitative Enzyme-Linked Immunosorbent Assay

Performed

Mon

Reported

1-15 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Serum separator tube.

Specimen Preparation

Separate serum from cells ASAP or within 2 hours of collection. Transfer 0.5 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Urine or plasma. Contaminated, heat-inactivated, severely hemolyzed or severely lipemic specimens.

Remarks
Stability

After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)

Reference Interval
0-19 Units Negative
20-39 Units Equivocal
40 Units or greater Positive

Interpretive Data

The presence of the anti-C1q IgG antibody may be associated with increased risk of lupus nephritis or with systemic lupus erythematosus (SLE) global activity. Anti-C1q antibodies are not specific for SLE; strong clinical correlation with disease is recommended.

Compliance Statement A: For laboratory developed tests using a manufacturer labeled ASR as the reagent providing the specificity of the assay. Analyte Specific Reagent. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, the FDA has determined that such clearance or approval is not necessary.

Note
Hotline History
N/A
CPT Codes

83516

Components
Component Test Code* Component Chart Name LOINC
2007602 Anti-C1q Antibody, IgG
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • C1q IgG Ab
Anti-C1q Antibody, IgG